Silvio Danese, Humanitas Clinical and Research Hospital, Milan, Italy. Article by Maria Dalby – The current paradigm for managing inflammatory conditions is to suppress the inflammatory response by… read more.
New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.
Update from the GEMINI study programme – by Maria Dalby Jean-Frédéric Colombel, Mount Sinai Hospital, New York, USA The GEMINI study programme is a large phase-3 clinical trial… read more.
Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.
Management of ulcerative colitis: putting patients at the centre – by Maria Dalby Iris Dotan (Tel Aviv Sourasky Medical Centre, Israel), Peter Irving (Guy’s and St Thomas’ NHS… read more.
ECCO-EFCCA Patient Guidelines – by Maria Dalby Marco Greco, Milan, Italy; Séverine Vermeire, University Hospital of Leuven, Belgium; Salvatore Leone, Palermo, Italy; Paolo Gionchetti, University of Bologna, Italy; Martin Kojinov, Sofia, Bulgaria; Axel… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
